DOD Bone Marrow Failure Idea Development Award | W81XWH 22 BMFRP IDA

Opportunity Information: Apply for W81XWH 22 BMFRP IDA

The DOD Bone Marrow Failure Idea Development Award (BMFRP IDA) is a research funding opportunity from the Department of Defense (Department of the Army, USAMRAA) aimed at sparking new, innovative lines of investigation in bone marrow failure (BMF) diseases. The program is built around the BMFRP mission of improving understanding and ultimately curing BMF diseases, and it is specifically structured to help investigators pursue fresh concepts that are scientifically grounded but not yet fully established. In practice, this means proposals should go beyond incremental progress and instead be positioned to open up genuinely new avenues of research that could reshape how the field thinks about prevention, diagnosis, or treatment.

A central expectation of the IDA is that the proposed work is both innovative and high impact. Innovation is defined broadly: projects can introduce new paradigms, challenge existing assumptions, or reframe longstanding problems from a different angle. The program is receptive to high-risk, high-reward approaches as long as the application makes a credible case that, if successful, the work would significantly move the field forward and could translate into meaningful improvements in patient care or quality of life. Impact is judged by whether the project tackles a central, critical question in BMF research or clinical care and whether the outcomes could materially advance current approaches to detecting, diagnosing, preventing, or treating BMF diseases.

Although this mechanism is meant to develop ideas, the research still needs to be rigorous. Applicants are expected to present a well-formulated, testable hypothesis supported by a strong scientific rationale, along with a clear, well-articulated research plan. Preliminary data are allowed but not required. If applicants include unpublished results from the PI or collaborators, or relevant published findings, that can strengthen feasibility. However, applications without preliminary data can still be competitive if they are supported by solid logic and a strong foundation in the existing literature.

The opportunity is open to both Established Investigators (EIs) and Early-Career Investigators (ECIs), with specific eligibility definitions. Established Investigators are independent researchers typically at or above the Associate Professor level (or equivalent), or Assistant Professors (or equivalent) who are 10 years or more from their first faculty appointment. EIs are expected to demonstrate BMF-related expertise through prior funding and publications and to show that the team has the right collaborations and effort committed to carry out the work successfully. Early-Career Investigators are independent Assistant Professors (or equivalent) who are less than 10 years from their first faculty appointment; postdoctoral fellows do not qualify. The program allows flexibility for extended family medical leave, which does not count against the 10-year window, but any related gaps should be clearly explained in the application materials. ECIs also need to demonstrate that they have the training and capability to execute the project, and they must show institutional commitment beyond money, such as protected research time, independent lab space, and support for collaborations.

Team expertise is treated as a core review element rather than a secondary consideration. The application should clearly show bone marrow failure disease expertise either through the PI directly, the assembled research team, or formal collaborations. Collaborations should be documented, and the level of effort for the PI (whether EI or ECI) should match what is realistically needed for the scope of work. Overall, the IDA is designed for applicants who can pair bold scientific thinking with a credible plan and the right people to push a promising idea toward translational relevance.

Administratively, the opportunity number is W81XWH 22 BMFRP IDA and it falls under CFDA 12.420. The funding instrument type listed includes grants and cooperative agreements, and eligibility is broadly described as unrestricted (open to any entity type) as long as any additional eligibility conditions in the full announcement are met. The posting indicates an expected number of awards of six. The original opportunity timeline shows a creation date of May 4, 2022 and an original closing date of September 23, 2022. The award ceiling is shown as 0 in the provided listing, which often signals that the maximum award amount is defined elsewhere in the full program announcement or depends on project scope and budget rules rather than being stated in that summary field.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Bone Marrow Failure Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 04, 2022.
• Applicants must submit their applications by Sep 23, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 BMFRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: